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INTRODUCTION: Autophagy enables cells to recycle long-lived proteins or damaged organelles. Beclin 1, the mammalian orthologue of
the yeast Apg6/Vps30 gene, functions as a scaffold for the formation of autophagosomes.
MATERIALS AND METHODS: The immunohistochemical patterns of Beclin 1 expression and their prognostic relevance were studied in
formalin-fixed tissues from 155 patients with colorectal adenocarcinoma treated with surgery alone.
RESULTS: Using the weak homogeneous expression of Beclin 1 in normal colonic tissues as a basis for assessing tumours, the following
grouping/staining patterns were recognised in colorectal carcinomas: a normal-like pattern in 62 of 155 (40%) cases, an
underexpression pattern in 24 of 155 (15.5%) cases, extensive overexpression of Beclin 1 in 33 of 155 (21.3%) tumours and limited
overexpression of the protein in 36 of 155 (23.2%) tumours. Extensive overexpression of Beclin 1 was significantly linked with
overexpression of HIF1a and LDH5, as well as with high histological grade, vascular invasion and nodal involvement. Furthermore,
patients with extensive over- or underexpression of Beclin 1 had a significantly poorer overall survival compared with the other two
groups (Po0.0001). Beclin 1 had an independent prognostic relevance in multivariate analysis.
CONCLUSIONS: Beclin 1 has an important role in growth and metastasis of colorectal cancer. Loss of Beclin 1 expression (allelic loss or microRNA
regulatory activity, as suggested in the literature) defines poor progn o s i sp r e s u m a b l yb yp r o m o t i n ga n t i -apoptotic pathways, while over-
expression of the protein, being linked with tumour hypoxia and acidity, also defines subgroups of tumours with aggressive clinical behaviour.
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Autophagy is an important cellular function that enables the
recycling of long-lived proteins or damaged organelles (Klionsky
and Emr, 2000). Autophagy is characterised by the formation of
double-membrane vacuoles containing cytoplasmic constituents,
the autophagosomes. These are fused with lysosomes, which sub-
sequently degrade the sequestered material. In this way, the cell-
ular homoeostasis is preserved by preventing the accumulation of
waste material, which, at the same time, is degraded and used as
metabolic fuel. Various stress factors, including hypoxia, acidity
and starvation, accentuate the autophagic machinery. Oncogenes
and tumour suppressor genes are also involved in the regulation of
autophagy (Maiuri et al, 2009).
Cancer cells are, therefore, exposed to a variety of external and
internal stimuli that would intensify their autophagic activity. The
role of autophagy in the growth and metastasis of human
carcinomas is poorly understood. Although autophagy is a major
cell survival pathway, excessive activation leads to massive
degradation of cellular components, shifting the balance to self-
destruction and autophagic cell death (type II programmed cell
death). The autophagic cancer cell response to ionising radiation
and chemotherapy seems to affect the efficacy of these agents, but
such interactions are very complex depending on the agent and the
cell type studied (Zois and Koukourakis, 2009).
The core machinery of autophagy is composed of three major
functional groups: (i) Atg9 and its cycling system; (ii) a phosphati-
dylinositol 3-OH kinase (PI3K) complex; and (iii) an ubiquitin-like
protein system, which includes two ubiquitin proteins, the Atg12
and Atg8 (mammalian homologue MAP1LC3/LC3) (Mari and
Reggiori, 2007). In mammalian cells, the class III PI3K complex is
composed of various interacting proteins (UVRAG, Bif-1 and
Ambra-1) and the vacuolar protein-sorting proteins Vps34, Vps15
and Beclin 1/Atg6. Beclin 1 is the mammalian orthologue of the
yeast Apg6/Vps30 gene (Cao and Klionsky, 2007). It functions as a
scaffold for the formation of the PI3K complex, which is one of the
first components recruited by a developing autophagosome, and is
essential for autophagy. Beclin 1 is present in intra-cytoplasmic
organelles, such as the trans-Golgi network, endoplasmic reticu-
lum, mitochondria and the perinuclear membrane (Kihara et al,
2001; Cao and Klionsky, 2007).
In this study, we assessed the patterns of Beclin 1 expression in a
series of colorectal carcinomas with scope to investigate the
clinicopathological role of this protein in the early steps of
autophagosome formation.
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The material comprised formalin-fixed paraffin-embedded tissues
from 155 consecutive patients with operable stage II/III colorectal
adenocarcinoma treated with surgery alone. This is a retrospective
study based on archival material. The cases analysed represent a
sequential series of patients according to the archival number
given at the Department of Cellular Pathology, Oxford, UK, upon
receipt of the surgical specimen. The selection of this specific
material was performed to include patients who underwent surgery
alone without chemotherapy of radiotherapy at a time when these
adjunctive therapies were not the standard of treatment. In this
way, the analysis of data in this older series will reflect the actual
impact of the tumour biology on the clinical outcome, without
introducing into our model unpredictable differences in terms of
chemo- or radiosensitivity of individual carcinomas, which would
then need randomised comparison to interpret. All patients in the
series underwent surgery between 1990 and 1994 having a follow-
up of at least 3 years after surgery. Patients with perioperative
death were excluded from this study.
According to the TNM AJCC/UICC staging system, 80 cases were
stage IIA (T3N0) and 75 were stage III (T3-N1,2). Altogether, 49 of
the 155 patients had tumours with rectal involvement. In all, 66 of
them were female and 89 were male. The median age was 69 (range
37–87) years. The median follow-up was 24 (range 3–43) months.
Immunohistochemistry
For the detecton of Beclin 1, the rabbit monoclonal antibody
EPR1733Y (ab51031, Abcam, Cambridge, UK) was used at a
dilution 1:50. This is a synthetic peptide corresponding to
residues near the C-terminus of human Beclin 1. The concentra-
tion of the aforementioned antibody was determined after
performing a pilot study in which the dilutions of the primary
antibody varied from 1:10 to 1:400, and the incubation time was
75min at room temperature vs overnight incubation at 41C.
Sections were cut at 3mm and stained as follows: They were
dewaxed and rehydrated in graded alcohol solutions. For heat-
induced epitope retrieval, the sections were placed in citrate buffer
(1:10 dilution, pH 7.2) and heated at 1201Cf o r3  5min.
Endogenous peroxidase activity was neutralised using Peroxidase
Block for 5min. The nonspecific binding was blocked by pre-
incubation with Protein Block for 5min at room temperature
(Novocastra Laboratories Ltd., Newcastle upon Tyne, UK). Slides
were then incubated overnight at 41C with the primary antibody
diluted 1:50 (Abgent, San Diego, CA, USA). The slides were washed
with PBS (2 5min) and then incubated with Post Primary Block
(that enhances penetration of the subsequent polymer reagent) for
30min at room temperature (Novocastra Laboratories Ltd.), and
then washed with PBS for 2 5min and incubated with NovoLink
polymer for 30min at room temperature (Novocastra Laboratories
Ltd.). This recognises mouse and rabbit immunoglobulins and
detects any tissue-bound primary antibody. After extensive washing
with PBS (2 5min), the colour reaction was developed in
3,30-diaminobenzidine for 5min. The sections were then counter-
stained with hematoxylin, dehydrated and mounted.
Normal rabbit immunoglobulin G was substituted for the
primary antibody as negative control. Staining with omission of
the primary antibody was also performed as negative control.
Assessment of Beclin 1 expression
Beclin 1 was expressed in both the nuclei and cytoplasm of cancer
cells. The percentage of cells with positive nuclei was recorded in
all available optical fields at  200 magnification, and the mean
value was used to score each case. The median value of these was
used to group cases into two categories of low (omedian) and
high (Xmedian) nuclear reactivity.
The intensity and extent of cytoplasmic expression was also
recorded in all optical fields. The intensity ranged from negative
through weak to strong. The whole tissue section, including tumour
and adjacent normal colon area, was examined in all  200 optical
fields available. Given that the normal colonic epithelium consis-
tently showed a weak cytoplasmic expression of Beclin 1, this grade
of intensity in tumour cells was considered as ‘normal-like’
(Figure 1A). Taking this weak staining as a criterion, there were
tumour cells with loss of Beclin 1 expression and those over-
expressing the protein. The percentage of cells with normal-like
intensity and those with under- or overexpression was recorded in all
 200 optical fields and the mean value was used to score each case.
Combining the results of extent and intensity of staining, the
tumours were allocated to the following four categories:
1. ‘Normal-like’ pattern of staining: o10% of the neoplastic cells
expressed a strong, and 490% expressed a weak cytoplasmic
Beclin 1 reactivity (Figure 1B).
2. Overexpression of Beclin 1: when 410% showed a strong
cytoplasmic expression; this was considered as being (2A)
extensive when 450% of neoplastic cells showed a strong
Beclin 1 reactivity, or (2B) limited when 10–50% of tumour
cells showed a similar reaction (Figure 1C). In the 2A pattern,
the strong cytoplasmic expression was present in the context of
a prevalent weak expression in the tissue sample, whereas in the
2B the strong cytoplasmic expression was the prevalent pattern.
It was therefore postulated that such a classification would be
important to identify divergent biological behaviour.
3. Underexpression of Beclin 1: 450% of tumour cells were
negative (Figure 1D).
In all cases (normal colonic tissues, four tumour categories
of immunohistochemical expression), sporadic nuclear expres-
sion of Beclin 1 is also evident in parallel with the cytoplasmic
staining of cells.
Assessment of hypoxia/acidity
The presence of hypoxia and acidity was assessed immunohisto-
chemically by detecting the expression of HIF1a and LDH5. The
HIF1a is a key transcription factor stabilised under hypoxic
conditions because of the the reduction of its degradation rate
by the ubiquitin-proteasome pathway (Salceda and Caro, 1997).
LDH5, which is composed of five LDH-A subunits, is the LDH
isoenzyme with the highest affinity to catalyse the anaerobic
transformation of pyruvate to lactate that is extruded outside the
cells through the activity of mocoarboxylate transporters, acidify-
ing the extracellular milieu (Holbrook et al, 1975).
HIF1a was detected after using the ESEE 122 monoclonal antibody
(University of Oxford), whereas the detection of LDH5 was achieved
by the ab9002 polyclonal antibody (Abcam). The immunohisto-
chemical technique and the scoring system for these proteins has
been previously reported (Koukourakis et al, 2006). Cases were
grouped into categories of low and high expression, using a
previously reported grading system (Koukourakis et al, 2006).
Assessment of vascular invasion and necrosis
The presence of cancer cells within vascular channels was detected
in hematoxylin–eosin sections. Areas of necrosis covering 410%
of the tissue section was scored as ‘extensive’, whereas all other
cases were scored as being of ‘limited/no’ necrosis.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 5.0
and the Instat 3.1 package (GraphPad Software Inc., San Diego,
CA, USA). A Fisher’s exact test was used for testing relationships
between categorical variables (contingency tables) as appropriate.
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continuous variables. The Kaplan–Meier survival curves were
used to assess the impact of various variables in the overall
survival (OS) of patients. A Cox proportional hazard model was
used to assess the effect of assessed parameters on death events.
A P-value of o0.05 was used for significance.
RESULTS
Expression patterns
Normal colon area showed invariably a weak Beclin 1 staining of
epithelial cells (Figure 1A), and this intensity was considered as
normal-like for the subsequent scoring of cancer areas.
The typical patterns of Beclin 1expression (negative, weak
cytoplasmic, strong cytoplasmic and nuclear) are shown in Figure
1B–D. The median percentage of cells with strong cytoplasmic
expression was 10% (range 0–90%), whereas that for nuclear
expression was 0% (range 0–80%).
Using the scoring system described in the Material and Methods
section, 33 of 155 (21.3%) cases had extensive overexpression of
Beclin 1, 36 of 155 (23.2%) showed limited overexpression, 62 of
155 (40%) showed a normal-like pattern and 24 of 155 (15.5%)
were underexpressed. Of the 155 cases, 67 (43.2%) showed nuclear
expression of Beclin 1 in X10% of cancer cells
Analysis of nuclear expression according to the cytoplasmic
patterns showed that Beclin 1 overexpression (limited and
extensive) was linked significantly with nuclear expression
(Table 1; Po0.02).
Association with histological variables
The association of cytoplasmic Beclin 1 expression patterns with
histopathological variables is shown in Table 2. Extensive Beclin 1
overexpression was significantly linked with nodal involvement,
high histological grade and vascular invasion.
High nuclear expression was significantly linked with high
histological grade (51 of 67 vs 54 of 88; P¼0.05), and there was a
similar trend for such an association with necrosis (49 of 67 vs 52
of 88; P¼0.08).
Association with hypoxia parameters
Table 2 shows the association of Beclin 1 with HIF1a and LDH5
expression. Extensive overexpression of Beclin 1 was significantly
linked with high LDH5 expression compared with all other
subgroups (Po0.01). Both limited and extensive overexpression
were linked with high HIF1a expression.
Survival analysis
Figure 2A shows Kaplan–Meier disease-specific OS curves,
stratified according to the cytoplasmic expression patterns.
Patients with extensive overexpression and those with under-
expression of Beclin 1 had a significantly poorer OS compared
with other two groups (Po0.0001). The 3-year OS was 89%, 77.7%,
43.3% and 31% for patients exhibiting normal-like, limited
overexpression, extensive overexpression and underexpression
patterns, respectively. The nuclear expression of Beclin 1 was not
related to prognosis (Figure 2B).
Table 1 Relation of cytoplasmic patterns of Beclin 1 to nuclear
expression
Nuclear expression
Cytoplasmic patterns 0–9% X10% P-value
1 – Normal-like 41 22 2 vs 1; 0.02
2A – Limited overexpression 14 22 2 vs 3; 0.01
2B – Extensive overexpression 16 16 —
3 – Underexpression 18 6 —
Figure 1 Immunohistochemical patterns of Beclin 1 expression: (A) Normal colonic tissue showing weak cytoplasmic expression of Beclin 1 in parallel
with sporadic staining of nuclei. (B) Normal-like Beclin 1 expression pattern in a colorectal adenocarcinoma. (C) Overexpression of Beclin 1 in the
cytoplasm and nuclei of a colorectal adenocarcinoma. (D) Downregulation of Beclin 1 expression in a colorectal adenocarcinoma with sporadic weak
staining of nuclei.
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variables known to affect prognosis (stage, differentiation
and necrosis), a multivariate analysis was performed to assess
the independence of Beclin 1 prognosis. It was shown that the
cytoplasmic patterns of Beclin 1, together with those of nodal
involvement and vascular invasion, were strong independent
predictors of death events (model 1; Table 3). In another model
(model 2), which, in addition to the above parameters, the HIF1a
and LDH5 were included, the LDH5 expression was emerged as an
independent prognostic marker.
Despite the low number of cases, double stratification Kaplan–
Meier survival analysis, according to Beclin 1 and stage, showed
that Beclin 1 patterns of expression maintained their prognostic
relevance separately in stage II and in stage III subgroups (data not
shown).
DISCUSSION
The role of the autophagy in the clinical outcome of human
malignancies remains obscure. Most of studies focus on Beclin 1,
an essential protein for the initiation of autophagosome formation
(Cao and Klionsky, 2007). It serves as a scaffold, which, by binding
to other proteins, forms pre-autophagosomal structures. Beclin 1 is
reported to reside in the trans-Golgi network, endoplasmic
reticulum and the mitochondria (Kihara et al, 2001; Cao and
Klionsky, 2007). It is therefore expected that Beclin 1 will show a
cytoplasmic patterns of immunohistochemical expression. This
was, indeed, confirmed in our study, although an additional
nuclear localisation of the protein was also noted in a subset of
colorectal tumours. The latter pattern has been also reported by
Li et al (2009) in a series of colon carcinomas. Beclin 1 contains
a leucine-rich nuclear export signal motif, and Liang et al (2001)
showed that the CRM1 nuclear export pathway is an important
regulator of Beclin 1 autophagic and tumour suppression function.
The existing data on the prognostic role of Beclin 1 in human
carcinomas are rather scarce and contradictory. Ahn et al (2007)
reported that Beclin 1 is poorly expressed in normal colon and
gastric mucosa, a finding that is in accordance with the current
study. Overexpression of Beclin 1 in related carcinomas was a very
frequent event and the authors suggested that inactivation or loss
of Beclin 1 expression may not occur in gastrointestinal
carcinomas (Ahn et al, 2007). Li et al found that higher levels of
Beclin 1 expression are linked with better prognosis in patients
with stage III colorectal cancer (Liang et al, 2001). A study in
hepatocellular carcinomas, on the other hand, suggested that the
loss of Beclin 1 in tumour cells was the most prominent expression
pattern, which was also related to recurrent disease (Ding et al,
2008). Liang et al (1999) found a relative underexpression of Beclin
1 in breast carcinomas compared with normal breast tissues,
suggesting that decreased expression of autophagic proteins may
contribute to the development or progression of breast cancer.
Beclin 1 levels are decreased in high-grade brain tumours and,
Table 2 Relation of cytoplasmic Beclin 1 expression patterns to
histopathological and hypoxia parameters
Cytoplasmic patterns
Parameter
Normal-
like
Limited
over-
expression
Extensive
over-
expression
Under-
expression P-value
Stage
T3-N0 34 20 12 14 0.04
a
T3-N1,2 28 16 21 10 —
Grade
12 6 1 2 4 8 o0.05
b
2/3 36 24 29 16 —
Necrosis
No 22 6 14 12 o0.05
c
Yes 40 30 19 12 —
Vascular invasion
No 50 26 20 16 0.03
d
Yes 12 10 13 8 —
HIF1a
Low 26 6 7 12 o0.05
e
High 36 30 26 12 —
LDH5
Low 20 12 2 8 o0.01
f
High 42 24 31 16 —
aExtensive vs all other.
bExtensive vs each one of the other groups.
cLimited vs each
one of the other groups.
dExtensive vs normal.
eExtensive and limited overexpression
vs each one of the rest.
fExtensive overexpression vs each one of the rest.
A. Normal-like (62 pts)
B. Limited overexpression (36 pts)
C. Extensive overexpression (33 pts)
D. Negative (24 pts)
C vs A; P<0.0001
C vs B; P=0.02
C vs D; P=0.71
D vs A; P<0.0001
D vs B; P=0.01
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Figure 2 Kaplan–Meier overall survival curves according to the
cytoplasmic patterns (A) and the nuclear expression (B). Pts, patients.
Table 3 Multivariate analysis of death events (model 1: Beclin 1 and
histopathological variables; model 2: significant variables of model 1
including hypoxia variables)
Model 1 Model 2
Variable t ratio P-value t ratio P-value
Nodal involvement 4.04 o0.0001 4.89 o0.0001
Grade (2/3 vs 1) 0.09 0.92 — —
Vascular (yes vs no) 3.13 0.002 2.71 0.007
Necrosis (yeas vs no) 0.03 0.30 — —
Beclin 1cytoplasmic 5.05 o0.0001 4.97 o0.0001
Beclin 1 nuclear 0.08 0.93 — —
LDH5 — — 4.18 o0.0001
HIF1a — — 0.69 0.48
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2007; Pirtoli et al, 2009). Indeed, allelic deletions of Beclin 1 are
common in breast cancer cell lines and promote tumourigenesis
in experimental models (Qu et al, 2003). Moreover, microRNAs,
such as miT-30a, seem also to be involved in the negative
regulation of Beclin 1 (Zhu et al, 2009).
Therefore, it appears that both under- and overexpression of
Beclin 1 may exist in human carcinomas. Indeed, in our study, by
taking the intensity of normal colonic staining as a marker for
tumour reactivity, we managed to identify four distinct patterns
of Beclin 1 expression: underexpression of Beclin 1, which was
evident in 15.5% of tumours, the normal-like pattern, which
was present in 40.6%, and overexpression of Beclin 1, which was
detected in the remaining 43.9% of cases. This latter category,
however, was further split into two equal-numbered subgroups of
limited and extensive overexpression. Extensive overexpression
of Beclin 1 was significantly linked with histological markers
of tumour aggressiveness, such as nodal involvement, high histolo-
gical grade and vascular invasion. Survival analysis confirmed the
ominous prognostic role of extensive Beclin 1 overexpression, but
a similarly poor survival was also showed in tumours with loss of
Beclin 1 expression.
The above analysis suggests the existence of two distinct
biological pathways of Beclin 1 activity, both linked with tumour
aggressiveness. Loss of Beclin 1 expression may reflect allelic gene
deletions (Aita et al, 1999). As Beclin 1 interacts with members of
the bcl-2 protein acting as a tumour suppressor (Cao and Klionsky,
2007), potentiation of the anti-apoptotic machinery may account,
at least in part, for the poor outcome of patients having Beclin1-
negative colonic tumours and would not necessarily be related to
severe environmental stress.
Maintenance of Beclin1 expression, however, may not necessa-
rily be associated with good prognosis. Overexpression of the
protein, often linked with its nuclear presence, especially when
extensively present in tumours, also defined poor prognosis.
However, nuclear expression per se was not linked with prognosis,
suggesting that the cytoplasmic presence of Beclin 1 is more potent
marker of aggressiveness. If the nuclear presence also has a
biological relevance, this was masked by the prominent prognostic
impact of the cytoplasmic overexpression. Although a direct
involvement of an activated autophagic machinery in cancer cell
survival and growth cannot be excluded, Beclin 1 overexpression
may be an indirect marker of tumour aggressiveness. Extensive
overexpression was linked with HIF1a and LDH5 upregulation,
indicating hypoxic tumours and an acidic intra-tumoral environ-
ment. Chen et al (2009) also found a direct association between
Beclin 1 and HIF1a expression in oesophageal carcinoma.
Upregulation of Beclin 1 may be a response to adverse intra-
tumoral conditions demanding intensified autophagic activity for
cancer cells to recycle proteins and damaged organelles in order to
survive. Samokhvalov et al (2008) showed that RNAi knockdown of
Beclin 1 function decreases survival under hypoxic stress. Over-
expression of Beclin 1 may therefore be a survival response to
adverse intra-tumoral conditions and could indicate tumour
aggressiveness linked with hypoxia and acidity. In the current study,
multivariate analysis of parameters, including HIF1a and LDH5,
showed that Beclin 1 had an independent prognostic relevance so
that a direct effect of Beclin 1 in defining tumour aggressiveness is
implied, aside to its association with hypoxia and acidity.
The current series of patients, being treated with surgery alone,
has been intentionally chosen to study the biological role of Beclin
1 in the clinical course of the disease, avoiding bias from
interactions of chemotherapy or radiotherapy with the autophagic
machinery. Whether the specific Beclin 1 expression patterns
further define responsiveness to such therapies remains an
important question to answer in subsequent studies in randomised
series of patients receiving postoperative chemo- or radiotherapy.
Nevertheless, from a therapeutic point of view, Beclin 1 emerges as
a target for development of molecular therapies. Silencing the
Beclin 1 protein may prove lethal for tumours whose survival relies
on intensified autophagic cell response, such as tumours with high
hypoxic cell content. Song et al (2009) found that treatment of
hepatoma cells with Beclin 1 siRNA resulted in chemosensitisation
under hypoxic conditions. Blocked autophagy also sensitises
cancer cells to radiation (Apel et al, 2008). In a recent study,
Kim et al (2008) showed that Beclin 1 is linked with HIF1a
expression and poor survival of nasopharyngeal cancer patients
undergoing radiotherapy and chemotherapy. In a contrary study,
tumours with repressed Beclin 1 expression seem to bear increased
inherent radioresistance because of increased anti-apoptotic
potential, so that targeting the bcl-2 or p53 pathway may be a
suitable means for radiosensitisation (Anai et al, 2007).
It is concluded that Beclin 1 has an important role in growth and
metastasis of human colorectal cancer. Loss of Beclin 1 expression,
presumably related to allelic loss of the gene or microRNA
regulatory activity as suggested in the literature, defines poor
prognosis by promoting anti-apoptotic pathways, whereas over-
expression of the protein, being linked with tumour hypoxia and
acidity, also defines subgroups of tumours with an aggressive
clinical behaviour. Elucidating the autophagy mechanisms in cancer
cells and careful classification of patients may prove of importance
in the development of such targeted therapeutic strategies.
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